Top

Published in:

Open Access 01-06-2019 | Diabetes | Review

Cardiovascular Risk in Type 1 Diabetes Mellitus

Authors: Jonathan Schofield, Jan Ho, Handrean Soran

Published in: Diabetes Therapy | Issue 3/2019

Abstract

Type 1 diabetes mellitus (T1DM) is associated with premature cardiovascular disease (CVD), but the underlying mechanisms remain poorly understood. The American Diabetes Association and the European Association for the Study of Diabetes recently updated their position statement on the management of type 2 diabetes mellitus (T2DM) to include additional focus on cardiovascular risk; improved management of risk factors in T1DM is also needed. There are important differences in the pathophysiology of CVD in T1DM and T2DM. Hyperglycaemia appears to have a more profound effect on cardiovascular risk in T1DM than T2DM, and other risk factors appear to cause a synergistic rather than additive effect, so achievement of treatment targets for all recognized risk factors is crucial to reducing cardiovascular risk. Here we discuss the evidence for addressing established cardiovascular risk factors, candidate biomarkers and surrogate measurements, and possible interventions.

Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316–22. https://doi.org/10.2337/dc14-0920.CrossRefPubMed

Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59(12):3216–22. https://doi.org/10.2337/db10-0862.CrossRefPubMedPubMedCentral

Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(3):198–206. https://doi.org/10.1016/S2213-8587(14)70248-7.CrossRefPubMed

Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29(4):798–804.CrossRef

Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972–82. https://doi.org/10.1056/NEJMoa1408214.CrossRefPubMed

Costacou T, Edmundowicz D, Prince C, Conway B, Orchard TJ. Progression of coronary artery calcium in type 1 diabetes mellitus. Am J Cardiol. 2007;100(10):1543–7. https://doi.org/10.1016/j.amjcard.2007.06.050.CrossRefPubMedPubMedCentral

Winocour PH, Durrington PN, Ishola M, Anderson DC, Cohen H. Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987;294(6588):1648–51.CrossRef

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018. https://doi.org/10.1007/s00125-018-4729-5.CrossRefPubMedPubMedCentral

Rawshani A, Rawshani A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;377(3):300–1. https://doi.org/10.1056/NEJMc1706292.CrossRefPubMed

10.

Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321. https://doi.org/10.1371/journal.pmed.1001321.CrossRefPubMedPubMedCentral

11.

Colhoun HM, Rubens MB, Underwood SR, Fuller JH. The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J Am Coll Cardiol. 2000;36(7):2160–7.CrossRef

12.

Dabelea D, Kinney G, Snell-Bergeon JK, et al. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes. 2003;52(11):2833–9.CrossRef

13.

Harjutsalo V, Thomas MC, Forsblom C, Groop PH, FinnDiane Study Group. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab. 2018. https://doi.org/10.1111/dom.13456.CrossRefPubMed

14.

Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care. 2006;29(11):2528–38. https://doi.org/10.2337/dc06-1161.CrossRefPubMed

15.

Zgibor JC, Piatt GA, Ruppert K, Orchard TJ, Roberts MS. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care. 2006;29(8):1860–5. https://doi.org/10.2337/dc06-0290.CrossRefPubMed

16.

Conway B, Costacou T, Orchard T. Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? Diab Vasc Dis Res. 2009;6(4):223–30. https://doi.org/10.1177/1479164109336041.CrossRefPubMedPubMedCentral

17.

Vistisen D, Andersen GS, Hansen CS, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the Steno Type 1 Risk Engine. Circulation. 2016;133(11):1058–66. https://doi.org/10.1161/CIRCULATIONAHA.115.018844.CrossRefPubMed

18.

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Risk factors for cardiovascular disease in type 1 diabetes. Diabetes. 2016;65(5):1370–9. https://doi.org/10.2337/db15-1517.CrossRef

19.

Rawshani A, Sattar N, Franzen S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477–86. https://doi.org/10.1016/S0140-6736(18)31506-X.CrossRefPubMed

20.

de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843–63. https://doi.org/10.2337/dc14-1720.CrossRefPubMedPubMedCentral

21.

Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53. https://doi.org/10.1056/NEJMoa052187.CrossRefPubMed

22.

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–502. https://doi.org/10.1161/CIRCULATIONAHA.116.022194.CrossRefPubMedPubMedCentral

23.

Renard CB, Kramer F, Johansson F, et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Investig. 2004;114(5):659–68. https://doi.org/10.1172/JCI17867.CrossRefPubMed

24.

Hero C, Svensson AM, Gidlund P, Gudbjornsdottir S, Eliasson B, Eeg-Olofsson K. LDL cholesterol is not a good marker of cardiovascular risk in type 1 diabetes. Diabet Med. 2016;33(3):316–23. https://doi.org/10.1111/dme.13007.CrossRefPubMed

25.

Soedamah-Muthu SS, Chaturvedi N, Toeller M, et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 2004;27(2):530–7.CrossRef

26.

Professional Practice Committee. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S3. https://doi.org/10.2337/dc18-Sppc01.CrossRef

27.

Jenkins AJ, Best JD, Klein RL, Lyons TJ. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev. 2004;20(5):349–68. https://doi.org/10.1002/dmrr.491.CrossRefPubMed

28.

Dean JD, Durrington PN. Treatment of dyslipoproteinaemia in diabetes mellitus. Diabet Med. 1996;13(4):297–312. https://doi.org/10.1002/(SICI)1096-9136(199604)13:4%3c297:AID-DIA82%3e3.0.CO;2-Q.CrossRefPubMed

29.

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–44.CrossRef

30.

Taskinen MR. LDL-cholesterol, HDL-cholesterol or triglycerides—which is the culprit? Diabetes Res Clin Pract. 2003;61(Suppl 1):S19–26.CrossRef

31.

Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363–79.CrossRef

32.

Steinbrecher UP, Zhang HF, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med. 1990;9(2):155–68.CrossRef

33.

Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol. 2011;22(4):254–61. https://doi.org/10.1097/MOL.0b013e328348a43f.CrossRefPubMed

34.

Soedamah-Muthu SS, Vergouwe Y, Costacou T, et al. Predicting major outcomes in type 1 diabetes: a model development and validation study. Diabetologia. 2014;57(11):2304–14. https://doi.org/10.1007/s00125-014-3358-x.CrossRefPubMedPubMedCentral

35.

McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–33. https://doi.org/10.1016/S0140-6736(08)61076-4.CrossRefPubMed

36.

Tolonen N, Forsblom C, Makinen VP, et al. Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study. Diabetes Care. 2014;37(8):2374–82. https://doi.org/10.2337/dc13-2873.CrossRefPubMed

37.

Durrington PN. Serum high density lipoprotein cholesterol subfractions in type I (insulin-dependent) diabetes mellitus. Clin Chim Acta. 1982;120(1):21–8.CrossRef

38.

Durrington PN. Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta. 1980;104(1):11–23.CrossRef

39.

Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30(2):151–5. https://doi.org/10.1161/ATVBAHA.108.179226.CrossRefPubMed

40.

Schofield JD, France M, Ammori B, Liu Y, Soran H. High-density lipoprotein cholesterol raising: does it matter? Curr Opin Cardiol. 2013;28(4):464–74. https://doi.org/10.1097/HCO.0b013e328362210d.CrossRefPubMed

41.

Costacou T, Evans RW, Orchard TJ. High-density lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol. 2011;5(5):387–94. https://doi.org/10.1016/j.jacl.2011.06.011.CrossRefPubMedPubMedCentral

42.

Miller RG, Secrest AM, Ellis D, Becker DJ, Orchard TJ. Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2013;36(12):3999–4006. https://doi.org/10.2337/dc13-1142.CrossRefPubMedPubMedCentral

43.

Larkin ME, Backlund JY, Cleary P, et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabet Med. 2010;27(4):451–8. https://doi.org/10.1111/j.1464-5491.2010.02972.x.CrossRefPubMed

44.

Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987;294(6588):1651–4.CrossRef

45.

Jenkins AJ, Yu J, Alaupovic P, et al. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort. J Diabetes Complicat. 2013;27(5):447–53. https://doi.org/10.1016/j.jdiacomp.2013.06.002.CrossRefPubMedPubMedCentral

46.

Frej C, Mendez AJ, Ruiz M, et al. A shift in ApoM/S1P between HDL-particles in women with type 1 diabetes mellitus is associated with impaired anti-inflammatory effects of the ApoM/S1P complex. Arterioscler Thromb Vasc Biol. 2017;37(6):1194–205. https://doi.org/10.1161/ATVBAHA.117.309275.CrossRefPubMed

47.

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–9. https://doi.org/10.1001/jama.2009.801.CrossRefPubMed

48.

Kollerits B, Auinger M, Reisig V, et al. Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diabetes Care. 2006;29(7):1661–3. https://doi.org/10.2337/dc06-0546.CrossRefPubMed

49.

Purnell JQ, Marcovina SM, Hokanson JE, et al. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes. 1995;44(10):1218–26.CrossRef

50.

Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25. https://doi.org/10.1038/nature10146.CrossRefPubMed

51.

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.CrossRef

52.

Deckert V, Brunet A, Lantoine F, et al. Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18(7):1054–60.CrossRef

53.

Muis MJ, Bots ML, Grobbee DE, Stolk RP. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med. 2005;22(2):118–26. https://doi.org/10.1111/j.1464-5491.2004.01416.x.CrossRefPubMed

54.

Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28(5):463–91. https://doi.org/10.1210/er.2007-0006.CrossRefPubMed

55.

Potenza MA, Addabbo F, Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab. 2009;297(3):E568–77. https://doi.org/10.1152/ajpendo.00297.2009.CrossRefPubMed

56.

Kyrgios I, Maggana I, Giza S, et al. Suboptimal glycaemic control enhances the risk of impaired prothrombotic state in youths with type 1 diabetes mellitus. Diabetes Vasc Dis Res. 2014;11(3):208–16. https://doi.org/10.1177/1479164114528821.CrossRef

57.

Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal. 2009;11(12):3071–109. https://doi.org/10.1089/ARS.2009.2484.CrossRefPubMed

58.

van Eupen MG, Schram MT, Colhoun HM, Scheijen JL, Stehouwer CD, Schalkwijk CG. Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. Cardiovasc Diabetol. 2013;12:149. https://doi.org/10.1186/1475-2840-12-149.CrossRefPubMedPubMedCentral

59.

Hanssen NM, Wouters K, Huijberts MS, et al. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J. 2014;35(17):1137–46. https://doi.org/10.1093/eurheartj/eht402.CrossRefPubMed

60.

Maahs DM, Snell-Bergeon JK, Hokanson JE, et al. Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes. Diabetes Technol Ther. 2010;12(1):25–33. https://doi.org/10.1089/dia.2009.0086.CrossRefPubMedPubMedCentral

61.

van der Laan SW, Fall T, Soumare A, et al. Cystatin C and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2016;68(9):934–45. https://doi.org/10.1016/j.jacc.2016.05.092.CrossRefPubMedPubMedCentral

62.

Bjornstad P, Wiromrat P, Johnson RJ, et al. Serum uromodulin predicts less coronary artery calcification and diabetic kidney disease over 12 years in adults with type 1 diabetes: the CACTI study. Diabetes Care. 2018. https://doi.org/10.2337/dc18-1527.CrossRefPubMedPubMedCentral

63.

Peeters SA, Engelen L, Buijs J, et al. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc Diabetol. 2015;14:31. https://doi.org/10.1186/s12933-015-0195-2.CrossRefPubMedPubMedCentral

64.

Peeters SA, Engelen L, Buijs J, et al. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol. 2017;16(1):55. https://doi.org/10.1186/s12933-017-0539-1.CrossRefPubMedPubMedCentral

65.

Ferreira I, Hovind P, Schalkwijk CG, Parving HH, Stehouwer CDA, Rossing P. Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort. Diabetologia. 2018;61(1):231–41. https://doi.org/10.1007/s00125-017-4470-5.CrossRefPubMed

66.

Hoffman RP, Dye AS, Huang H, Bauer JA. Glycemic variability predicts inflammation in adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2016;29(10):1129–33. https://doi.org/10.1515/jpem-2016-0139.CrossRefPubMedPubMedCentral

67.

Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33(6):1389–94. https://doi.org/10.2337/dc09-2082.CrossRefPubMedPubMedCentral

68.

Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106(8):913–9.CrossRef

69.

Emerging Risk Factors Consortium, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40. https://doi.org/10.1016/s0140-6736(09)61717-7.CrossRef

70.

Schalkwijk CG, Poland DC, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999;42(3):351–7. https://doi.org/10.1007/s001250051162.CrossRefPubMed

71.

Sousa GR, Pober D, Galderisi A, et al. Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus: a DCCT/EDIC cohort-based study. Circulation. 2018. https://doi.org/10.1161/circulationaha.118.036068.CrossRef

72.

Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care. 2011;34(5):1238–44. https://doi.org/10.2337/dc11-0079.CrossRefPubMedPubMedCentral

73.

Almeida FK, Esteves JF, Gross JL, Biavatti K, Rodrigues TC. Severe forms of retinopathy predict the presence of subclinical atherosclerosis in type 1 diabetes subjects. Arq Bras Cardiol. 2011;97(4):346–9.CrossRef

74.

Soliman EZ, Backlund JY, Bebu I, et al. Progression of electrocardiographic abnormalities in type 1 diabetes during 16 years of follow-up: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. J Am Heart Assoc. 2016;5(3):e002882. https://doi.org/10.1161/JAHA.115.002882.CrossRefPubMedPubMedCentral

75.

O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14–22. https://doi.org/10.1056/nejm199901073400103.CrossRefPubMed

76.

Yamasaki Y, Kawamori R, Matsushima H, et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes. 1994;43(5):634–9.CrossRef

77.

Lyons TJ, Jenkins AJ, Zheng D, et al. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima–media thickness. Diabet Med. 2006;23(9):955–66. https://doi.org/10.1111/j.1464-5491.2006.01905.x.CrossRefPubMed

78.

Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima–media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348(23):2294–303. https://doi.org/10.1056/NEJMoa022314.CrossRefPubMed

79.

Rathsman B, Rosfors S, Sjoholm A, Nystrom T. Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes. Cardiovasc Diabetol. 2012;11:145. https://doi.org/10.1186/1475-2840-11-145.CrossRefPubMedPubMedCentral

80.

Shoji T, Hatsuda S, Tsuchikura S, et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis. 2009;202(2):582–8. https://doi.org/10.1016/j.atherosclerosis.2008.04.042.CrossRefPubMed

81.

Holte KB, Svanteson M, Hanssen KF, Haig Y, Solheim S, Berg TJ. Undiagnosed coronary artery disease in long-term type 1 diabetes. The Dialong study. J Diabetes Complicat. 2019. https://doi.org/10.1016/j.jdiacomp.2019.01.006.CrossRefPubMed

82.

Bjornstad P, Eckel RH, Pyle L, Rewers M, Maahs DM, Snell-Bergeon JK. Relation of combined non-high-density lipoprotein cholesterol and apolipoprotein B with atherosclerosis in adults with type 1 diabetes mellitus. Am J Cardiol. 2015;116(7):1057–62. https://doi.org/10.1016/j.amjcard.2015.07.020.CrossRefPubMedPubMedCentral

83.

Snell-Bergeon JK, Roman R, Rodbard D, et al. Glycaemic variability is associated with coronary artery calcium in men with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabet Med. 2010;27(12):1436–42. https://doi.org/10.1111/j.1464-5491.2010.03127.x.CrossRefPubMedPubMedCentral

84.

Fahrmann ER, Adkins L, Loader CJ, et al. Severe hypoglycemia and coronary artery calcification during the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Res Clin Pract. 2015;107(2):280–9. https://doi.org/10.1016/j.diabres.2014.10.007.CrossRefPubMed

85.

Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44. https://doi.org/10.1056/NEJMoa1800256.CrossRefPubMed

86.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC Study 30-year follow-up. Diabetes Care. 2016;39(5):686–93. https://doi.org/10.2337/dc15-1990.CrossRef

87.

Steineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234. https://doi.org/10.1136/bmj.h3234.CrossRefPubMedPubMedCentral

88.

Jamiolkowska M, Jamiolkowska I, Luczynski W, Tolwinska J, Bossowski A, Glowinska Olszewska B. Impact of real-time continuous glucose monitoring use on glucose variability and endothelial function in adolescents with type 1 diabetes: new technology-new possibility to decrease cardiovascular risk? J Diabetes Res. 2016;2016:4385312. https://doi.org/10.1155/2016/4385312.CrossRefPubMed

89.

Origin Trial Investigators, Mellbin LG, Ryden L, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34(40):3137–44. https://doi.org/10.1093/eurheartj/eht332.CrossRef

90.

Pietri AO, Dunn FL, Grundy SM, Raskin P. The effect of continuous subcutaneous insulin infusion on very-low-density lipoprotein triglyceride metabolism in type I diabetes mellitus. Diabetes. 1983;32(1):75–81.CrossRef

91.

Tames FJ, Mackness MI, Arrol S, Laing I, Durrington PN. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis. 1992;93(3):237–44.CrossRef

92.

Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–72. https://doi.org/10.1016/S0140-6736(09)60697-8.CrossRefPubMed

93.

Bebu I, Braffett BH, Pop-Busui R, et al. The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. Diabetologia. 2017;60(10):2084–91. https://doi.org/10.1007/s00125-017-4374-4.CrossRefPubMedPubMedCentral

94.

Cholesterol Treatment Trialists Consortium, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/s0140-6736(10)61350-5.CrossRef

95.

Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96. https://doi.org/10.1016/S0140-6736(04)16895-5.CrossRefPubMed

96.

Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1.CrossRef

97.

Cholesterol Treatment Trialists Consortium, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25. https://doi.org/10.1016/s0140-6736(08)60104-x.CrossRef

98.

Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–16.CrossRef

99.

Hero C, Rawshani A, Svensson AM, et al. Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes. Diabetes Care. 2016;39(6):996–1003. https://doi.org/10.2337/dc15-2450.CrossRefPubMed

100.

NICE. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Institute for Health and Clinical Excellence; 2014.

101.

Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373(15):1476–7. https://doi.org/10.1056/NEJMc1509363.CrossRefPubMed

102.

Leiter LA, Cariou B, Muller-Wieland D, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19(12):1781–92. https://doi.org/10.1111/dom.13114.CrossRefPubMedPubMedCentral

103.

The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;1:1. https://doi.org/10.1056/nejmoa1804989.CrossRef

104.

Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018. https://doi.org/10.1056/nejmoa1812792.CrossRefPubMedPubMedCentral

105.

NICE. Type 1 diabetes in adults: diagnosis and management. London: National Institute for Health and Care Excellence; 2015.

106.

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. https://doi.org/10.1016/s0140-6736(10)60674-5.CrossRef

107.

de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–84. https://doi.org/10.2337/dci17-0026.CrossRefPubMed

108.

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. https://doi.org/10.1093/eurheartj/ehw106.CrossRefPubMedPubMedCentral

109.

Joint British Societies’ Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(Suppl 2):ii1–67. https://doi.org/10.1136/heartjnl-2014-305693.CrossRef

110.

Purnell JQ, Braffett BH, Zinman B, et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care. 2017;40(12):1756–62. https://doi.org/10.2337/dc16-2523.CrossRefPubMedPubMedCentral

111.

Seeger JP, Thijssen DH, Noordam K, Cranen ME, Hopman MT, Nijhuis-van der Sanden MW. Exercise training improves physical fitness and vascular function in children with type 1 diabetes. Diabetes Obes Metab. 2011;13(4):382–4. https://doi.org/10.1111/j.1463-1326.2011.01361.x.CrossRefPubMed

112.

Herbst A, Kordonouri O, Schwab KO, Schmidt F, Holl RW, Germany DPVIotGWGfPD. Impact of physical activity on cardiovascular risk factors in children with type 1 diabetes: a multicenter study of 23,251 patients. Diabetes Care. 2007;30(8):2098–100. https://doi.org/10.2337/dc06-2636.CrossRefPubMed

113.

Ranjan A, Schmidt S, Damm-Frydenberg C, Holst JJ, Madsbad S, Norgaard K. Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: a randomized open-label crossover trial. Diabetes Obes Metab. 2017;19(10):1479–84. https://doi.org/10.1111/dom.12953.CrossRefPubMed

114.

Schoenaker DA, Toeller M, Chaturvedi N, Fuller JH, Soedamah-Muthu SS, EPCS Group. Dietary saturated fat and fibre and risk of cardiovascular disease and all-cause mortality among type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2012;55(8):2132–41. https://doi.org/10.1007/s00125-012-2550-0.CrossRefPubMedPubMedCentral

115.

Ahola AJ, Saraheimo M, Freese R, et al. Association between adherence to dietary recommendations and high-sensitivity C-reactive protein level in type 1 diabetes. Diabetes Res Clin Pract. 2017;126:122–8. https://doi.org/10.1016/j.diabres.2017.02.012.CrossRefPubMed

116.

ASC Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;1:1. https://doi.org/10.1056/nejmoa1804988.CrossRef

117.

Rawshani A, Rawshani A, Franzen S, et al. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2017;135(16):1522–31. https://doi.org/10.1161/CIRCULATIONAHA.116.025961.CrossRefPubMedPubMedCentral

118.

Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597–609. https://doi.org/10.1016/S2213-8587(17)30194-8.CrossRefPubMedPubMedCentral

119.

Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702–10. https://doi.org/10.2337/dc16-0691.CrossRefPubMed

120.

Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204–12. https://doi.org/10.1111/j.1464-5491.2004.01319.x.CrossRefPubMed

121.

Ceriello A, Piconi L, Quagliaro L, et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care. 2005;28(3):632–7.CrossRef

122.

Fattah H, Vallon V. The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus. Drugs. 2018;78(7):717–26. https://doi.org/10.1007/s40265-018-0901-y.CrossRefPubMedPubMedCentral

123.

McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61(10):2126–33. https://doi.org/10.1007/s00125-018-4671-6.CrossRefPubMedPubMedCentral

124.

Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(7):1755–61. https://doi.org/10.1111/dom.13260.CrossRefPubMed

125.

Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914.CrossRefPubMed

Title: Cardiovascular Risk in Type 1 Diabetes Mellitus
Authors: Jonathan Schofield
Jan Ho
Handrean Soran
Publication date: 01-06-2019
Publisher: Springer Healthcare
Keywords: Diabetes
Type 1 Diabetes
Published in: Diabetes Therapy / Issue 3/2019
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-019-0612-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial

Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus

Establishing Expert, Multi-Disciplinary, Peer-Reviewed Consensus to Lead a Paradigm Shift in Optimal Blood Glucose Management

How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol

Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study

Downregulation of T-Cell Transcription Factors in Adult Latent Autoimmune Diabetes with High-Titer Glutamic Acid Decaroxylase Antibody

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage